

SUPPORTING INFORMATION FOR

Environmentally benign peptide synthesis using liquid-assisted ball-milling: application to the synthesis of Leu-enkephalin

Julien Bonnamour, Thomas-Xavier Métro,* Jean Martinez and Frédéric Lamaty*

Institut des Biomolécules Max Mousseron (IBMM), UMR 5247 CNRS-Universités Montpellier 1 et 2,
Bâtiment Chimie (17), Université Montpellier 2, Place Eugène Bataillon, 34095 Montpellier cedex 5,
France.

E-mail: txmetro@um2.fr; frederic.lamaty@univ-montp2.fr

Table of Contents

· General	S1
· ¹ H and ¹³ C spectra	S14
· Kinetic study	S48
· Chiral HPLC chromatograms	S50
· EcoScale calculations	S52
· Milling-load calculations	S54
· References	S55

General: All reagents were purchased from Aldrich Chemical Co. and Isochem and used without further purification excepted for Boc-AA-NCA that were dissolved in EtOAc and washed with saturated NaHCO₃ aqueous solution before use. The milling treatments were carried out in a Retsch Mixer Mill 200. ¹H NMR spectra were recorded on a Bruker Avance DPX 200 MHz spectrometer and are reported in ppm using solvent as an internal standard (CDCl₃ at 7.24 ppm). Data are reported as s = singlet, d = doublet, t = triplet, m = multiplet or overlap of non-equivalent resonances; coupling constant in Hz; integration. ¹³C NMR spectra were recorded on a Bruker Avance AM 75 MHz spectrometer and are reported in ppm using solvent as an internal standard (CDCl₃ at 77.2 ppm). Mass spectra were obtained by LC-MS with ESI using a Water Alliance 2695 as LC, coupled to a Waters ZQ spectrometer with electrospray source, a simple quadrupole analyzer and a UV Waters 2489 detector. HRMS analyse was performed on a Q-ToF (Waters, ESI, 2001) spectrometer. Enantiomeric excess was measured using a

Beckman Coulter System Gold 126 Solvent Module HPLC machine and System Gold 168 Detector with 4.6 mm x 250 mm Daicel Chiralpak OD columns using *n*-hexane and 2-propanol as solvents.


General procedure using Boc-protected α -amino acid *N*-carboxyanhydrides (Boc-AA-NCA; named as general procedure A): The Boc-protected α -amino acid *N*-carboxyanhydride species (1 eq), α -amino ester hydrochloride (1 eq), NaHCO₃ (1 eq) and EtOAc (between 1.1 and 1.6 μ L per mg of solid reactants depending on the reaction) were introduced in a 10 mL stainless steel grinding bowl with one stainless steel ball (10 mm diameter). The bowl was closed and placed 20 minutes within the mixer mill at 30 Hz. Then, the suspension was diluted with EtOAc and washed two times with aqueous saturated sodium carbonate solution and two times with 1N aqueous HCl solution. Then the organic layer was dried on MgSO₄, filtered, concentrated under *vacuo* and dried over P₂O₅ to obtain the final product.

General procedure using Boc-protected α -amino acid hydroxysuccinimide esters (Boc-AA-OSu; named as general procedure B): The Boc-protected α -amino acid hydroxysuccinimide ester (1 eq), α -amino ester hydrochloride (1 eq), NaHCO₃ (1 eq) and EtOAc (between 1.1 and 1.6 μ L per mg of solid reactants depending on the reaction) were introduced in a 10 mL stainless steel grinding bowl with one stainless steel ball (10 mm diameter). The bowl was closed and placed 20 minutes within the mixer mill at 30 Hz. Then, 2 mL of 1N aqueous NaOH solution was added and the reactor was put in the mixer mill for 5 min at 30 Hz. Afterwards, the suspension was diluted with EtOAc and washed two times with 1N aqueous NaOH solution and two times with 1N aqueous HCl solution. Then the organic layer was dried on MgSO₄, filtered, concentrated under *vacuo* and dried over P₂O₅ to obtain the final product.

Boc-Phe-Leu-OMe¹

Following general procedure A, Boc-Phe-NCA (111.3 mg, 0.382 mmol), NaHCO₃ (32.1 mg, 0.382 mmol), EtOAc (300 μ L) and HCl·H-Leu-OMe (69.4 mg, 0.382 mmol) were used. Boc-Phe-Leu-OMe was recovered as a white solid (142.6 mg, 95%).


Following general procedure, Boc-Phe-OSu (138.4 mg, 0.382 mmol), NaHCO₃ (32.1 mg, 0.382 mmol), EtOAc (300 μ L) and HCl·H-Leu-OMe (69.4 mg, 0.382 mmol) were used. Boc-Phe-Leu-OMe was recovered (123.8 mg, 83 %) as a white solid.



¹H NMR (300 MHz, CDCl₃): δ = 7.26–7.12 (m, 5H), 6.16 (d, *J* = 8.1 Hz, 1H), 4.98–4.81 (m, 1 H), 4.55–4.45 (m, 1H), 4.32–4.22 (dd, *J* = 6.8, 13.7 Hz, 1H), 3.62 (s, 3H), 3.00 (d, *J* = 6.8 Hz, 2H), 1.62–1.03 (m with singlet, 12H), 0.83 (apparent t, *J* = 5.7 Hz, 6H) ppm; ¹³C NMR (75 MHz, CDCl₃): δ = 173.0, 171.2, 155.5, 136.8, 129.5, 128.7, 127.0, 80.2, 55.7, 52.3, 50.9, 41.6, 38.3, 28.4, 24.8, 22.9, 22.0 ppm; MS (ESI): *m/z* 393.2 [*M*+H]⁺.

Boc-Leu-Leu-OBn²


Following general procedure A, Boc-Leu-NCA (88.8 mg, 0.345 mmol), NaHCO₃ (29.0 mg, 0.345 mmol), EtOAc (300 μ L) and *p*-TsOH·H-Leu-OBn (135.8 mg, 0.345 mmol) were used. Boc-Leu-Leu-OBn was recovered as a white solid (140.0 mg, 93%).



^1H NMR (200 MHz, CDCl_3): δ = 7.33–7.22 (m, 5H), 6.48 (d, J = 8.4 Hz, 1H), 5.12 (d, J = 1.2 Hz, 2H), 4.90 (d, J = 8.6 Hz, 1H), 4.64–4.52 (m, 1H), 4.10–3.90 (m, 1H), 1.68–1.30 (m, 15H), 0.89–0.78 (m, 12H) ppm; ^{13}C NMR (75 MHz, CDCl_3): δ = 172.7, 172.5, 155.9, 135.6, 128.8, 128.6, 128.4, 80.2, 67.2, 53.1, 51.0, 41.6, 41.1, 28.5, 24.9, 24.8, 23.0, 22.3, 22.0 ppm; MS (ESI): m/z 435.2 [$M+\text{H}$] $^+$.

Boc-Val-Phe-OMe³


Following general procedure A, Boc-Val-NCA (96.3 mg, 0.396 mmol), NaHCO_3 (33.3 mg, 0.396 mmol), EtOAc (300 μL) and $\text{HCl}\cdot\text{H-Phe-OMe}$ (85.5 mg, 0.396 mmol) were used. Boc-Val-Phe-OMe was recovered as a white solid (126.3 mg, 84 %).



^1H NMR (200 MHz, CDCl_3): δ = 7.25–7.00 (m, 5H), 6.44–6.33 (m, 1H), 5.07–4.92 (m, 1H), 4.85–4.73 (m, 1H), 3.89–3.78 (m, 1H), 3.63 (s, 3H), 3.07–2.99 (m, 2H), 2.09–1.92 (m, 1H), 1.37 (s, 9H), 0.88–0.74 (m, 6H) ppm; ^{13}C NMR (75 MHz, CDCl_3): δ = 171.9, 171.5, 155.9, 135.9, 129.4, 128.8, 127.3, 80.0, 60.0, 53.3, 52.4, 38.1, 31.0, 28.5, 19.3, 17.8 ppm; MS (ESI): m/z 379.2 [$M+\text{H}$] $^+$.

Boc-Leu-Pro-OBn⁴


Following general procedure A, Boc-Leu-NCA (92.1 mg, 0.358 mmol), NaHCO_3 (30.1 mg, 0.358 mmol), EtOAc (300 μL) and $\text{HCl}\cdot\text{H-Pro-OBn}$ (86.6 mg, 0.358 mmol) were used. Boc-Leu-Pro-OBn was recovered as an oil (135.0 mg, 90%).



^1H NMR (200 MHz, CDCl_3): δ = 7.32–7.17 (m, 5H), 5.17–4.97 (m, 3H), 4.56–4.32 (m, 2H), 3.76–3.40 (m, 2H), 2.21–2.07 (m, 1H), 2.05–1.83 (m, 3H), 1.77–1.55 (m, 1H), 1.43–1.28 (m with singulet, 11H), 0.89 (d, J = 6.5 Hz, 3H), 0.83 (d, J = 6.5 Hz, 3H) ppm; ^{13}C NMR (75 MHz, CDCl_3) (several conformers): δ = 172.1, 172.0, 155.9, 135.7, 128.7, 128.5, 128.3, 79.7, 67.1, 59.0, 50.5, 46.9, 42.1, 29.1, 28.5, 25.1, 24.7, 23.6, 21.9 ppm; MS (ESI): m/z 419.2 [$M+\text{H}$] $^+$.

Boc-Ile-Ile-OMe⁵


Following general procedure A, Boc-Ile-NCA (107.5 mg, 0.418 mmol), NaHCO_3 (35.1 mg, 0.418 mmol), EtOAc (300 μL) and $\text{HCl}\cdot\text{H-Ile-OMe}$ (75.9 mg, 0.418 mmol) were used. Boc-Ile-Ile-OMe was recovered as a white solid (142.5 mg, 95%).



^1H NMR (200 MHz, CDCl_3): δ = 6.43 (d, J = 8.8 Hz, 1H), 5.06 (d, J = 8.6 Hz, 1H), 4.53 (dd, J = 4.8, 8.4 Hz, 1H), 3.90 (dd, J = 6.8, 8.6 Hz, 1H), 3.66 (s, 3H), 1.98–1.68 (m, 2H), 1.42–1.33 (m, 11H), 1.20–0.95 (m, 2H), 0.89–0.79 (m, 12H) ppm; ^{13}C NMR (75 MHz, CDCl_3): δ = 172.3, 171.7, 155.9, 80.0, 59.5, 56.6, 52.2, 38.0, 37.2, 28.5, 25.3, 25.0, 15.7, 15.6, 11.7, 11.5 ppm; MS (ESI): m/z 359.2 [$M+\text{H}$] $^+$.

Boc-Gly-Phe-OMe⁶


Following general procedure B, Boc-Gly-OSu (121.4 mg, 0.446 mmol), NaHCO₃ (37.5 mg, 0.446 mmol), EtOAc (300 μ L) and HCl·H-Phe-OMe (96.2 mg, 0.446 mmol) were used. Boc-Gly-Phe-OMe was recovered as an oil (143.9 mg, 96%).



¹H NMR (200 MHz, CDCl₃): δ = 7.25–6.99 (m, 5H), 6.82–6.72 (m, 1H), 5.37–5.27 (m, 1H), 4.84–4.73 (m, 1H), 3.72–3.63 (m, 2H), 3.61 (s, 3H), 3.02 (dd, J = 3.0, 5.6 Hz, 2H), 1.36 (s, 9H) ppm; ¹³C NMR (75 MHz, CDCl₃): δ = 171.9, 169.4, 156.0, 135.8, 129.2, 128.6, 127.1, 80.1, 53.2, 52.3, 44.1, 37.9, 28.3 ppm; MS (ESI): m/z 337.1 [$M+H$]⁺.

Boc-Gly-Pro-OBn


Following general procedure B, Boc-Gly-OSu (112.7 mg, 0.414 mmol), NaHCO₃ (35.8 mg, 0.414 mmol), EtOAc (300 μ L) and HCl·H-Pro-OBn (100.0 mg, 0.414 mmol) were used. Boc-Gly-Pro-OBn was recovered as an oil (145.1 mg, 97%).



¹H NMR (200 MHz, CDCl₃): δ = 7.46–7.34 (m, 5H), 5.55–5.40 (m, 1H), 5.32–5.13 (m, 2H), 4.68–4.58 (m, 1H), 4.11–3.89 (m, 2H), 3.72–3.43 (m, 2H), 2.35–1.80 (m, 4H), 1.49 (s, 9H) ppm; ¹³C NMR (75 MHz, CDCl₃) (major conformer): δ = 171.7, 167.7, 155.8, 135.6, 128.6, 128.3, 128.1, 79.6, 67.0, 59.0, 45.9, 43.0, 29.0, 28.4, 24.6 ppm; MS (ESI): m/z 363.1 [$M+H$]⁺, HRMS: m/z : calcd for C₁₉H₂₇N₂O₅: 363.1920; found: 363.1938.

Boc-Tyr(Bn)-Leu-OMe⁷


Following general procedure B, Boc-Tyr(Bn)-OSu (141.0 mg, 0.301 mmol), NaHCO₃ (25.3 mg, 0.301 mmol), EtOAc (300 μ L) and HCl·H-Leu-OMe (54.7 mg, 0.301 mmol) were ball-milled for 1 h. Boc-Tyr(Bn)-Leu-OMe was recovered as white solid (147.0 mg, 98%).



¹H NMR (200 MHz, CDCl₃): δ = 7.45–7.26 (m, 5H), 7.10 (d, J = 10.8 Hz, 2H), 6.87 (d, J = 10.5 Hz, 2H), 6.36 (d, J = 9.8 Hz, 1H), 5.13–4.95 (m, 3H), 4.63–4.47 (m, 1H), 4.39–4.22 (m, 1H), 3.66 (s, 3H), 2.99 (d, J = 8.0 Hz, 2H), 1.61–1.33 (m, 12H), 0.94–0.81 (m, 6H) ppm; ¹³C NMR (75 MHz, CDCl₃): δ = 173.0, 171.2, 157.9, 155.5, 137.1, 130.6, 128.9, 128.7, 128.1, 127.5, 115.1, 80.3, 70.1, 55.9, 52.4, 50.9, 41.7, 37.4, 28.4, 24.8, 22.9, 22.0 ppm; MS (ESI): m/z 499.2 [$M+H$]⁺.

Boc-Phe-Phe-OMe⁸

Following general procedure B, Boc-Phe-OSu (127.6 mg, 0.352 mmol), NaHCO₃ (29.6 mg, 0.352 mmol), EtOAc (300 μ L) and HCl·H-Phe-OMe (75.9 mg, 0.352 mmol) were used. Boc-Phe-Phe-OMe was recovered as a white solid (138.5 mg, 92%).




¹H NMR (200 MHz, CDCl₃): δ = 7.26–7.04 (m, 8H), 6.95–6.85 (m, 2H), 6.30 (d, J = 7.6 Hz, 1H), 4.98–4.82 (m, 1H), 4.77–4.64 (m, 1H), 4.34–4.19 (m, 1H), 3.59 (s, 3H), 3.06–2.87 (m, 4H), 1.32 (s, 9H) ppm; ¹³C NMR (75 MHz, CDCl₃): δ = 171.6, 171.0, 155.4, 136.7, 135.8, 129.5, 129.4, 128.8, 128.7, 127.3, 127.1, 80.4, 55.8, 53.5, 52.4, 38.5, 38.1, 28.4 ppm; MS (ESI): m/z 427.2 [$M+H$]⁺.

Boc-Phe-Leu-OBn⁹

Following general procedure B, Boc-Phe-OSu (116.0 mg, 0.320 mmol), NaHCO₃ (26.9 mg, 0.320 mmol), EtOAc (300 μ L) and *p*-TsOH·H-Leu-OBn (125.8 mg, 0.320 mmol) were used. Boc-Phe-Leu-OBn was recovered as a white solid (134.3 mg, 90%).


When realised on a 2.13 mmoles scale, Boc-Phe-OSu (771.9 mg, 2.13 mmol), NaHCO₃ (178.9 mg, 2.13 mmol), EtOAc (2000 μ L) and *p*-TsOH·H-Leu-OBn (838.7 mg, 2.13 mmol) were introduced in a 10 mL stainless steel grinding bowl with one stainless steel ball (10 mm diameter). The bowl was closed and placed 2 h within the mixer mill at 30 Hz. Then, 2 mL of 1N aqueous NaOH solution was added and the reactor was put in the mixer mill for 5 min at 30 Hz. Afterwards, the suspension was diluted with EtOAc and washed two times with 1N aqueous NaOH solution and two times with 1N aqueous HCl solution. Then the organic layer was dried on MgSO₄, filtered, concentrated under *vacuo* and dried over P₂O₅ to obtain the final product. Boc-Phe-Leu-OBn was recovered as a white solid (796.5 mg, 80%).



¹H NMR (200 MHz, CDCl₃): δ = 7.29–7.06 (m, 10H), 6.41 (d, J = 8.1 Hz, 1H), 5.12–4.97 (m, 3H), 4.61–4.44 (m, 1H), 4.38–4.21 (m, 1H), 3.05–2.86 (m, 2H), 1.55–1.15 (m with singlet, 12H), 0.85–0.72 (m, 6H) ppm; ¹³C NMR (75 MHz, CDCl₃): δ = 172.4, 171.2, 155.6, 136.8, 135.5, 129.5, 128.7, 128.5, 128.3, 127.0, 80.3, 67.1, 55.7, 51.0, 41.6, 38.3, 28.4, 24.8, 22.9, 22.0 ppm; MS (ESI): m/z 469.2 [$M+H$]⁺.

HCl·H-Leu-Leu-OBn


Boc-Leu-Leu-OBn (110.9 mg, 0.255 mmol) was submitted to gaseous HCl for 2 h. HCl·H-Leu-Leu-OBn was recovered as a white solid (94.6 mg, >99%).



¹H NMR (200 MHz, D₂O): δ = 7.50–7.29 (m, 5H), 5.18–5.14 (m, 2H), 4.53–4.43 (m, 1H), 4.01–3.92 (m, 1H), 1.73–1.48 (m, 6H), 0.97–0.72 (m, 12H) ppm; ¹³C NMR (75 MHz, D₂O): δ = 176.1, 172.9, 137.6, 131.40, 131.35, 131.0, 70.4, 54.4, 54.2, 42.4, 41.6, 32.2, 26.9, 26.2, 24.4, 24.1, 23.6, 23.3 ppm; MS (ESI): m/z 335.2 [$M+H$]⁺, HRMS: m/z : calcd for C₁₉H₃₁N₂O₃: 335.2335; found: 335.2302.

HCl·H-Val-Phe-OMe¹⁰


Boc-Val-Phe-OMe (90.9 mg, 0.240 mmol) was submitted to gaseous HCl for 2 h. HCl·H-Val-Phe-OMe was recovered as a white solid (75.6 mg, >99%).



¹H NMR (200 MHz, D₂O): δ = 7.44–7.25 (m, 5H), 4.79–4.72 (m, 1H, merged with HDO peak), 3.81–3.76 (m, 1H), 3.71 (s, 3H), 3.29–3.03 (m, 2H), 2.29–2.12 (m, 1H), 1.04–0.96 (m, 6H) ppm; ¹³C NMR (75 MHz, D₂O): δ = 173.2, 169.3, 136.3, 129.2, 128.9, 127.4, 58.3, 54.5, 53.0, 36.4, 30.1, 17.6, 16.7 ppm; MS (ESI): m/z 279.1 [$M+H$]⁺.

HCl·H-Leu-Pro-OBn


Boc-Leu-Pro-OBn (82.2 mg, 0.204 mmol) was submitted to gaseous HCl for 2 h. HCl·H-Leu-Pro-OBn was recovered as a white solid (72.2 mg, >99%).



¹H NMR (200 MHz, D₂O): δ = 7.48–7.36 (m, 5H), 5.20 (d, J = 12.0 Hz, 1H), 5.12 (d, J = 12.0 Hz, 1H), 4.60–4.51 (m, 1H), 4.24 (t, J = 6.9 Hz, 1H), 3.77–3.52 (m, 2H), 2.40–2.20 (m, 1H), 2.11–1.93 (m, 3H), 1.76–1.47 (m, 3H), 0.90 (d, J = 5.4 Hz, 3H), 0.87 (d, J = 5.4 Hz, 3H) ppm; ¹³C NMR (75 MHz, D₂O): δ = 173.4, 169.1, 135.1, 128.9, 128.6, 68.0, 59.9, 50.4, 47.6, 38.9, 28.7, 24.7, 23.8, 22.4, 20.4 ppm; MS (ESI): m/z 319.2 [$M+H$]⁺, HRMS: m/z : calcd for C₁₈H₂₇N₂O₃: 319.2022; found: 319.2018.

HCl·H-Ile-Ile-OMe⁵


Boc-Ile-Ile-OMe (92.2 mg, 0.257 mmol) was submitted to gaseous HCl for 2 h. HCl·H-Ile-Ile-OMe was recovered as a white solid (91.8 mg, >99%).



¹H NMR (200 MHz, D₂O): δ = 4.37 (d, J = 5.9 Hz, 1H), 3.92 (d, J = 5.7 Hz, 1H), 3.74 (s, 3H), 2.08–1.86 (m, 2H), 1.58–1.10 (m, 4H), 1.04–0.82 (m, 12H) ppm; ¹³C NMR (75 MHz, D₂O): δ = 176.1, 172.2, 60.4, 60.1, 55.2, 39.1, 38.7, 27.4, 26.6, 17.3, 16.5, 13.09, 13.07 ppm; MS (ESI): m/z 259.1 [$M+H$]⁺.

HCl·H-Gly-Phe-OMe¹¹


Boc-Gly-Phe-OMe (127.5 mg, 0.379 mmol) was submitted to gaseous HCl for 2 h. HCl·H-Gly-Phe-OMe was recovered as a white solid (103.3 mg, >99%).



^1H NMR (200 MHz, D_2O): δ = 7.44–7.23 (m, 5H), 4.85–4.74 (m, 1H, merged with HDO peak), 3.87–3.67 (m, 5H), 3.30–2.98 (m, 2H) ppm; ^{13}C NMR (75 MHz, D_2O): δ = 173.4, 166.8, 136.4, 129.3, 128.9, 127.4, 54.3, 53.1, 40.3, 36.8 ppm; MS (ESI): m/z 237.2 [$M+\text{H}$] $^+$.

HCl·H-Gly-Pro-OBn


Boc-Gly-Pro-OBn (95.0 mg, 0.262 mmol) was submitted to gaseous HCl for 2 h. HCl·H-Gly-Pro-OBn was recovered as a white solid (78.1 mg, >99%).



^1H NMR (200 MHz, D_2O): δ = 7.42 (s, 5H), 5.27–5.17 (m, 2H), 4.59–4.50 (m, 1H), 3.97–3.87 (m, 2H), 3.65–3.45 (m, 2H), 2.35–2.15 (m, 1H), 2.10–1.90 (m, 3H) ppm; ^{13}C NMR (75 MHz, D_2O): δ = 173.7, 165.7, 135.3, 129.0, 128.9, 128.4, 68.0, 59.6, 46.7, 40.4, 28.9, 24.3 ppm; MS (ESI): m/z 263.1 [$M+\text{H}$] $^+$, HRMS: m/z : calcd for $\text{C}_{14}\text{H}_{19}\text{N}_2\text{O}_3$: 263.1396; found: 263.1384.

HCl·H-Phe-Phe-OMe¹²


Boc-Phe-Phe-OMe (85.6 mg, 0.201 mmol) was submitted to gaseous HCl for 2 h. HCl·H-Phe-Phe-OMe was recovered as a white solid (72.5 mg, >99%).



^1H NMR (200 MHz, D_2O): δ = 7.46–7.18 (m, 10H), 4.71 (dd, J = 6.4, 8.0 Hz, 1H), 4.18 (t, J = 7.1 Hz, 1H), 3.67 (s, 3H), 3.24–2.96 (m, 4H) ppm; ^{13}C NMR (75 MHz, D_2O): δ = 172.7, 168.8, 136.2, 133.6, 129.5, 129.23, 129.20, 128.9, 128.1, 127.4, 54.4, 54.2, 53.0, 36.8, 36.7 ppm; MS (ESI): m/z 327.1 [$M+\text{H}$] $^+$.

HCl·H-Phe-Leu-OBn


Boc-Phe-Leu-OBn (145.0 mg, 0.309 mmol) was submitted to gaseous HCl for 2 h. HCl·H-Phe-Leu-OBn was recovered as a white solid (125.0 mg, >99%).



^1H NMR (200 MHz, D_2O): δ = 7.27–7.14 (m, 10H), 5.00 (s, 2H), 4.46–4.36 (m, 1H), 4.26 (t, J = 7.0 Hz, 1H), 3.16–2.94 (m, 2H), 1.60–1.38 (m, 3H), 0.83–0.73 (m, 6H) ppm; ^{13}C NMR (75 MHz, D_2O): δ = 170.7, 166.6, 132.9, 131.3, 127.3, 126.8, 126.5, 126.4, 126.1, 125.7, 65.3, 51.8, 49.5, 37.3, 34.6, 22.0, 19.6, 18.8 ppm; MS (ESI): m/z 369.2 [$M+\text{H}$] $^+$, HRMS: m/z : calcd for $\text{C}_{22}\text{H}_{29}\text{N}_2\text{O}_3$: 369.2178; found: 369.2173.

Boc-Leu-Leu-Leu-OBn


Following general procedure A, Boc-Leu-NCA (23.5 mg, 0.0913 mmol), NaHCO₃ (7.7 mg, 0.0913 mmol), EtOAc (100 μL) and HCl·H-Leu-Leu-OBn (33.9 mg, 0.0913 mmol) were used. Boc-Leu-Leu-Leu-OBn was recovered as a white solid (39.3 mg, 79%).



¹H NMR (200 MHz, CDCl₃): δ = 7.33–7.20 (m, 5H), 6.60–6.46 (m, 2H), 5.16 (d, *J* = 12.2 Hz, 1H), 5.08 (d, *J* = 12.2 Hz, 1H), 4.92 (d, *J* = 7.8 Hz, 1H), 4.64–4.48 (m, 1H), 4.44–4.31 (m, 1H), 4.08–3.89 (m, 1H), 1.67–1.30 (m, 18H), 0.91–0.73 (m, 18H) ppm; ¹³C NMR (75 MHz, CDCl₃): δ = 172.7, 172.4, 171.5, 155.7, 135.4, 128.6, 128.4, 128.3, 80.2, 67.0, 53.0, 51.6, 50.9, 41.3, 40.9, 40.8, 28.3, 24.7, 24.6, 22.9, 22.8, 22.0, 21.8 ppm; MS (ESI): *m/z* 548.4 [*M*+H]⁺, HRMS: *m/z*: calcd for C₃₀H₅₀N₃O₆: 548.3700; found: 548.3706.

Boc-Phe-Phe-Phe-OMe¹³


Following general procedure B, Boc-Phe-OSu (31.6 mg, 0.0872 mmol), NaHCO₃ (7.3 mg, 0.0872 mmol), EtOAc (100 μL) and HCl·H-Phe-Phe-OMe (31.6 mg, 0.0872 mmol) were used. Boc-Phe-Phe-Phe-OMe was recovered as a white solid (43.0 mg, 86%).



¹H NMR (200 MHz, CDCl₃): δ = 7.28–6.89 (m, 15H), 6.40 (d, *J* = 7.6 Hz, 1H), 6.17 (d, *J* = 7.4 Hz, 1H), 4.79 (d, *J* = 7.0 Hz, 1H), 4.69–4.57 (m, 1H), 4.49 (qd, *J* = 7.4 Hz, 1H), 4.30–4.16 (m, 1H), 3.59 (s, 3H), 3.05–2.76 (m, 6H), 1.30 (s, 9H) ppm; ¹³C NMR (75 MHz, CDCl₃): δ = 171.4, 171.2, 170.1, 155.6, 136.6, 136.4, 135.9, 129.5, 129.4, 128.9, 128.83, 128.79, 127.33, 127.25, 115.2, 80.6, 55.8, 54.5, 53.7, 52.5, 38.2, 38.0, 28.4 ppm; MS (ESI): *m/z* 574.3 [*M*+H]⁺.

Boc-Lys(Boc)-Gly-Pro-OBn


Following general procedure B, Boc-Lys(Boc)-OSu (37.5 mg, 0.085 mmol) NaHCO₃ (7.1 mg, 0.085 mmol), EtOAc (100 μL) and HCl·H-Gly-Pro-OBn (25.3 mg, 0.085 mmol) were used. Boc-Lys(Boc)-Gly-Pro-OBn was recovered as a white solid (39.7 mg, 79%).



¹H NMR (200 MHz, CDCl₃): δ = 7.33–7.25 (m, 5H), 6.93 (br s, 1H), 5.20–5.02 (m, 3H), 4.72–4.61 (m, 1H), 4.56–4.55 (m, 1H), 4.35–3.85 (m, 3H), 3.65–3.35 (m, 2H), 3.09–2.95 (m, 2H), 2.21–1.15 (m, 28H) ppm; ¹³C NMR (75 MHz, CDCl₃) (major conformers): δ = 172.2, 171.6, 166.9, 156.2, 155.7, 135.5, 128.6, 128.4, 128.1, 80.0, 79.1, 67.0, 59.0, 54.4, 46.0, 42.0, 40.1, 32.5, 29.7, 29.1, 28.5, 28.3, 24.6, 22.6 ppm; MS (ESI): *m/z* 591.4 [*M*+H]⁺, HRMS: *m/z*: calcd for C₃₀H₄₇N₄O₈: 591.3394; found: 591.3372.

Boc-Trp-Val-Phe-OMe


Following general procedure A, Boc-Trp-NCA (29.2 mg, 0.0885 mmol), NaHCO₃ (7.4 mg, 0.0885 mmol), EtOAc (100 μL) and HCl·H-Val-Phe-OMe (27.9 mg, 0.0885 mmol) were used. Boc-Trp-Val-Phe-OMe was recovered as a white solid (43.0 mg, 86%).



¹H NMR (200 MHz, CDCl₃): δ = 8.02 (s, 1H), 7.61 (d, *J* = 7.4 Hz, 1H), 7.30–6.86 (m, 9H), 6.20 (dd, *J* = 4.6, 7.6 Hz, 2H), 5.10 (d, *J* = 6.2 Hz, 1H), 4.67 (qd, *J* = 6.8 Hz, 1H), 4.44–4.32 (m, 1H), 4.09 (dd, *J* = 5.6, 8.0 Hz, 1H), 3.64 (s, 3H), 3.28–2.82 (m, 4H), 2.04–1.87 (m, 1H), 1.35 (s, 9H), 0.69 (d, *J* = 6.8 Hz, 3H), 0.56 (d, *J* = 6.8 Hz, 3H) ppm; ¹³C NMR (75 MHz, CDCl₃): δ = 172.0, 170.5, 155.8, 136.5, 136.1, 129.4, 128.9, 127.4, 123.4, 122.6, 120.1, 119.1, 111.4, 110.8, 77.4, 58.7, 55.5, 53.4, 52.5, 38.0, 30.5, 28.5, 19.1, 17.5 ppm; MS (ESI): *m/z* 565.3 [*M*+H]⁺, HRMS: *m/z*: calcd for C₃₁H₄₁N₄O₆: 565.3026; found: 565.3005.

Boc-Ile-Leu-Pro-OBn


Following general procedure A, Boc-Ile-NCA (24.2 mg, 0.094 mmol), NaHCO₃ (7.9 mg, 0.094 mmol), EtOAc (100 μL) and HCl·H-Leu-Pro-OBn (33.3 mg, 0.094 mmol) were used. Boc-Ile-Leu-Pro-OBn was recovered as an oil (42.8 mg, 86%).



¹H NMR (200 MHz, CDCl₃): δ = 7.33–7.21 (m, 5H), 6.44 (d, *J* = 8.6 Hz, 1H), 5.17–4.92 (m, 3H), 4.80–4.45 (m, 2H), 3.95–3.81 (m, 1H), 3.77–3.63 (m, 1H), 3.59–3.43 (m, 1H), 2.30–0.74 (m, 31H) ppm; ¹³C NMR (75 MHz, CDCl₃): δ = 171.9, 171.5, 171.0, 155.8, 135.7, 128.8, 128.5, 128.4, 80.0, 67.1, 59.5, 59.1, 49.1, 47.0, 42.1, 37.6, 29.2, 28.5, 25.1, 25.0, 24.7, 23.5, 22.0, 15.8, 11.6 ppm; MS (ESI): *m/z* 532.3 [*M*+H]⁺, HRMS: *m/z*: calcd for C₂₉H₄₆N₃O₆: 532.3387; found: 532.3386.

Boc-Ile-Ile-Ile-OMe


Following general procedure A, Boc-Ile-NCA (27.3 mg, 0.106 mmol), NaHCO₃ (8.9 mg, 0.106 mmol), EtOAc (100 μL) and HCl·H-Ile-Ile-OMe (31.2 mg, 0.106 mmol) were used. Boc-Ile-Ile-Ile-OMe was recovered as a white solid (43.2 mg, 86%).



¹H NMR (200 MHz, CDCl₃): δ = 6.66–6.51 (m, 2H), 5.15 (d, *J* = 8.4 Hz, 1H), 4.50 (dd, *J* = 5.0, 8.7 Hz, 1H), 4.33–4.23 (m, 1H), 3.92–3.83 (m, 1H), 3.66 (s, 3H), 1.90–1.68 (m, 4H), 1.55–0.73 (m, 32H) ppm; ¹³C NMR (75 MHz, CDCl₃): δ = 172.2, 172.0, 171.1, 156.0, 80.1, 59.7, 58.0, 56.7, 52.3, 37.9, 37.2, 37.1, 28.5, 25.3, 25.1, 25.0, 15.7, 15.6, 15.5, 11.7, 11.5, 11.4 ppm; MS (ESI): *m/z* 472.4 [*M*+H]⁺, HRMS: *m/z*: calcd for C₂₄H₄₆N₃O₆: 472.3387; found: 472.3380.

Boc-Gly-Gly-Phe-OMe¹⁴

Following general procedure B, Boc-Gly-OSu (34.6 mg, 0.127 mmol), NaHCO₃ (10.7 mg, 0.127 mmol), EtOAc (100 μ L) and HCl·H-Gly-Phe-OMe (34.7 mg, 0.127 mmol) were used. Boc-Gly-Gly-Phe-OMe was recovered as a white solid (37.1 mg, 74%).




¹H NMR (200 MHz, CDCl₃): δ = 7.26–6.92 (m, 6H), 6.85–6.77 (m, 1H), 5.35–5.26 (m, 1H), 4.82–4.70 (m, 1H), 3.88–3.68 (m, 4H), 3.63 (s, 3H), 3.13–2.91 (m, 2H), 1.38 (s, 9H) ppm; ¹³C NMR (75 MHz, CDCl₃): δ = 172.0, 170.3, 168.7, 156.3, 136.0, 129.4, 128.8, 127.4, 80.6, 53.6, 52.6, 44.4, 43.0, 38.0, 28.5 ppm; MS (ESI): m/z 394.1 [$M+H$]⁺.

Boc-Gly-Phe-Leu-OBn⁹

Following general procedure B, Boc-Gly-OSu (77.7 mg, 0.285 mmol), NaHCO₃ (23.9 mg, 0.285 mmol), EtOAc (300 μ L) and HCl·H-Phe-Leu-OBn (115.4 mg, 0.285 mmol) were used. Boc-Gly-Phe-Leu-OBn was recovered as an oil (139.1 mg, 93%).


When realised on a 1.90 mmoles scale, Boc-Gly-OSu (517.3 mg, 1.90 mmol), NaHCO₃ (159.6 mg, 1.90 mmol), *t*BuOAc (2000 μ L) and HCl·H-Phe-Leu-OBn (770.0 mg, 1.90 mmol) were introduced in a 10 mL stainless steel grinding bowl with one stainless steel ball (10 mm diameter). The bowl was closed and placed 40 min within the mixer mill at 30 Hz. Then, 2 mL of 1N aqueous NaOH solution was added and the reactor was put in the mixer mill for 5 min at 30 Hz. Afterwards, the suspension was diluted with EtOAc and washed two times with 1N aqueous NaOH solution and two times with 1N aqueous HCl solution. Then the organic layer was dried on MgSO₄, filtered, concentrated under *vacuo* and dried over P₂O₅ to obtain the final product. Boc-Gly-Phe-Leu-OBn was recovered as an oil (937.6 mg, 94%).



¹H NMR (200 MHz, CDCl₃): δ = 7.28–7.02 (m, 10H), 6.83 (d, J = 8.1 Hz, 1H), 6.59 (d, J = 8.0 Hz, 1H), 5.19 (t, J = 5.8 Hz, 1H), 5.00 (s, 2H), 4.64 (qd, J = 7.2 Hz, 1H), 4.52–4.40 (m, 1H), 3.68–3.60 (m, 2H), 2.98–2.91 (m, 2H), 1.53–1.27 (m with singlet, 12H), 0.81–0.69 (m, 6H) ppm; ¹³C NMR (75 MHz, CDCl₃): δ = 172.3, 170.7, 169.6, 156.2, 136.5, 135.6, 129.5, 128.8, 128.6, 128.4, 127.2, 80.5, 67.2, 54.3, 51.2, 44.4, 41.3, 38.3, 28.5, 24.9, 22.9, 22.1 ppm; MS (ESI): m/z 526.3 [$M+H$]⁺.

HCl·H-Leu-Leu-Leu-OBn


Boc-Leu-Leu-Leu-OBn (99.5 mg, 0.182 mmol) was submitted to gaseous HCl for 2 h. HCl·H-Leu-Leu-Leu-OBn was recovered as a white solid (87.9 mg, >99%).



¹H NMR (200 MHz, CDCl₃): δ = 7.48–7.37 (m, 5H), 5.24–5.14 (m, 2H), 4.52–4.37 (m, 2H), 4.03–3.94 (m, 1H), 1.77–1.45 (m, 9H), 0.98–0.79 (m, 18H) ppm; ¹³C NMR (75 MHz, CDCl₃): δ = 172.2, 171.9, 168.2, 133.6, 127.2, 127.1, 126.7, 66.0, 50.5, 50.1, 49.8, 38.2, 38.1, 37.4, 22.6, 22.5, 22.2, 20.4, 20.0, 19.9, 19.7, 18.9 ppm; MS (ESI): m/z 448.2 [$M+H$]⁺, HRMS: m/z : calcd for C₂₅H₄₂N₃O₄: 448.3175; found: 448.3166.

HCl·H-Gly-Phe-Leu-OBn


Boc-Gly-Phe-Leu-OBn (850.0 mg, 0.240 mmol) was submitted to gaseous HCl for 2 h. HCl·H-Gly-Phe-Leu-OBn was recovered as a white solid (747.0 mg, >99%).



^1H NMR (200 MHz, D_2O): δ = 7.48–7.14 (m, 10H), 5.11 (s, 2H), 4.68–4.58 (m, 1H), 4.40 (t, J = 6.8 Hz, 1H), 3.76 (d, J = 16.4 Hz, 1H), 3.66 (d, J = 16.4 Hz, 1H), 3.09–2.76 (m, 2H), 1.65–1.40 (m, 3H), 0.89–0.76 (m, 6H) ppm; ^{13}C NMR (75 MHz, D_2O): δ = 173.6, 172.8, 166.7, 136.0, 135.3, 129.2, 128.9, 128.8, 128.4, 127.3, 67.7, 54.9, 51.7, 40.3, 39.4, 37.3, 24.3, 22.0, 20.8 ppm; MS (ESI): m/z 426.3 $[M+H]^+$, HRMS: m/z : calcd for $\text{C}_{24}\text{H}_{32}\text{N}_3\text{O}_4$: 426.2393; found: 426.2392.

Boc-Leu-Leu-Leu-Leu-OBn

Following general procedure A, Boc-Leu-NCA (19.5 mg, 0.076 mmol), NaHCO_3 (6.4 mg, 0.076 mmol), EtOAc (100 μL) and HCl·H-Leu-Leu-Leu-OBn (36.6 mg, 0.076 mmol) were used. Boc-Leu-Leu-Leu-Leu-OBn was recovered as a white solid (47.8 mg, 96%).




^1H NMR (200 MHz, CDCl_3): δ = 7.32–7.15 (m, 5H), 6.84–6.72 (m, 2H), 6.66–6.54 (m, 1H), 5.15–4.86 (m, 3H), 4.62–4.25 (m, 3H), 4.05–3.87 (m, 1H), 1.75–1.15 (m, 21H), 0.95–0.65 (m, 24H) ppm; ^{13}C NMR (75 MHz, CDCl_3): δ = 173.1, 172.6, 171.94, 171.87, 156.3, 135.8, 128.7, 128.42, 128.36, 80.9, 67.1, 53.9, 52.4, 51.8, 51.1, 41.2, 41.0, 40.9, 40.7, 28.5, 25.04, 24.98, 24.92, 24.90, 23.19, 23.15, 22.2, 22.1, 22.0, 21.9 ppm; MS (ESI): m/z 661.3 $[M+H]^+$, HRMS: m/z : calcd for $\text{C}_{36}\text{H}_{61}\text{N}_4\text{O}_7$: 661.4540; found: 661.4576.

Boc-Gly-Gly-Phe-Leu-OBn

Following general procedure B, Boc-Gly-OSu (70.1 mg, 0.257 mmol), NaHCO_3 (21.6 mg, 0.257 mmol), EtOAc (300 μL) and HCl·H-Gly-Phe-Leu-OBn (118.7 mg, 0.257 mmol) were used. Boc-Gly-Gly-Phe-Leu-OBn was recovered as a white solid (143.4 mg, 96%).

When realised on a 0.55 mmole scale, Boc-Gly-OSu (272.3 mg, 0.554 mmol), NaHCO_3 (46.5 mg, 0.554 mmol), $t\text{BuOAc}$ (646 μL) and HCl·H-Gly-Phe-Leu-OBn (256.0 mg, 0.554 mmol) were introduced in a 10 mL stainless steel grinding bowl with one stainless steel ball (10 mm diameter). The bowl was closed and placed 40 min within the mixer mill at 30 Hz. Then, 2 mL of 1N aqueous NaOH solution was added and the reactor was put in the mixer mill for 5 min at 30 Hz. Afterwards, the suspension was diluted with EtOAc and washed two times with 1N aqueous NaOH solution and two times with 1N aqueous HCl solution. Then the organic layer was dried on MgSO_4 , filtered, concentrated under *vacuo* and dried over P_2O_5 to obtain the final product. Boc-Gly-Gly-Phe-Leu-OBn was recovered as a white solid (291.2 mg, 90%).




^1H NMR (200 MHz, CDCl_3): δ = 7.61–6.97 (m, 13H), 5.65–5.55 (m, 1H), 5.14–4.82 (m, 3H), 4.62–4.65 (m, 1H), 3.93–3.75 (m, 4H), 3.08–2.75 (m, 2H), 1.68–1.18 (m with singulet, 12H), 0.84–0.71 (m, 6H)

ppm; ^{13}C NMR (75 MHz, CDCl_3): $\delta = 172.6, 171.2, 169.9, 168.7, 156.3, 136.6, 135.6, 129.6, 128.8, 128.57, 128.56, 128.4, 127.0, 80.2, 67.2, 54.3, 51.2, 44.0, 43.2, 41.2, 39.0, 28.6, 25.0, 22.9, 22.1$ ppm; MS (ESI): m/z 583.3 $[M+H]^+$, HRMS: m/z : calcd for $\text{C}_{31}\text{H}_{43}\text{N}_4\text{O}_7$: 583.3132; found: 583.3115.

HCl·H-Gly-Gly-Phe-Leu-OBn


Boc-Gly-Gly-Phe-Leu-OBn (333.7 mg, 0.572 mmol) was submitted to gaseous HCl for 2 h. HCl·H-Gly-Gly-Phe-Leu-OBn was recovered as a white solid (297.1 mg, >99%).



^1H NMR (200 MHz, D_2O): $\delta = 7.24\text{--}7.04$ (m, 10H), 4.92 (s, 2H), 4.62 (t, $J = 7.4$ Hz, 1H), 4.41–4.31 (m, 1H), 3.92–3.70 (m, 4H), 3.03–2.75 (m, 2H), 1.55–1.35 (m, 3H), 0.79–0.62 (m, 6H) ppm; ^{13}C NMR (75 MHz, D_2O): $\delta = 175.7, 175.0, 172.9, 170.0, 138.7, 137.8, 131.8, 131.1, 130.9, 130.7, 129.5, 69.7, 57.1, 53.9, 44.6, 12.9, 12.2, 40.0, 26.8, 24.6, 23.5$ ppm; MS (ESI): m/z 483.3 $[M+H]^+$, HRMS: m/z : calcd for $\text{C}_{26}\text{H}_{35}\text{N}_4\text{O}_5$: 483.2607; found: 483.2625.

Boc-Tyr(Bn)-Gly-Gly-Phe-Leu-OBn


Following general procedure B, Boc-Tyr(Bn)-OSu (28.0 mg, 0.060 mmol), NaHCO_3 (5.0 mg, 0.060 mmol), EtOAc (100 μL) and HCl·H-Gly-Phe-Leu-OBn (31.1 mg, 0.060 mmol) were ball-milled during 1 h. Boc-Tyr(Bn)-Gly-Gly-Phe-Leu-OBn was recovered as a white solid (44.2 mg, 88%).



^1H NMR (600 MHz, CDCl_3): $\delta = 7.60\text{--}6.96$ (m, 21H), 6.83 (d, $J = 7.2$ Hz, 2H), 5.62–5.42 (m, 1H), 5.21–4.71 (m, 5H), 4.70–4.26 (m, 2H), 4.11–3.80 (m, 4H), 3.27–2.74 (m, 5H), 1.66–1.19 (m with singlet, 12H), 0.96–0.61 (m, 6H) ppm; ^{13}C NMR (75 MHz, CDCl_3): $\delta = 172.6, 172.5, 171.1, 169.2, 168.6, 158.0, 156.1, 137.1, 136.8, 135.6, 130.5, 129.7, 128.8, 128.6, 128.4, 128.2, 127.0, 115.1, 80.4, 70.1, 67.2, 56.1, 54.4, 51.2, 43.5, 43.3, 41.3, 39.0, 38.1, 28.6, 25.0, 23.0, 22.2$ ppm; MS (ESI): m/z 836.6 $[M+H]^+$, HRMS: m/z : calcd for $\text{C}_{47}\text{H}_{58}\text{N}_5\text{O}_9$: 836.4235; found: 836.4228.

Boc-Tyr(OH)-Gly-Gly-Phe-Leu-OH¹⁵

To a suspension of Boc-Tyr(Bn)-Gly-Gly-Phe-Leu-OBn (30.0 mg, 0.0359 mmol) in 10 mL of EtOH, palladium on activated carbon (10% Pd, 3 mg) was added and the mixture was allowed to stir overnight under a H_2 atmosphere. The suspension was filtered through Celite and the filtrate was evaporated to give Boc-Tyr(OH)-Gly-Gly-Phe-Leu-OH as a white solid (18.2 mg, 77%).




^1H NMR (200 MHz, MeOD): $\delta = 7.27\text{--}7.12$ (m, 5H), 7.00 (d, $J = 8.2$ Hz, 2H), 6.66 (d, $J = 8.2$ Hz, 2H), 4.62 (dd, $J = 4.8, 9.2$ Hz, 1H), 4.45–4.32 (m, 1H), 4.20–4.07 (m, 1H), 3.90–3.55 (m, 4H), 3.33–2.61 (m,

4H), 1.75–1.52 (m, 2H), 1.41–1.15 (m with singlet, 10H), 0.88 (t, $J = 6.6$ Hz, 6H) ppm; ^{13}C NMR (75 MHz, MeOD): $\delta = 175.5, 173.5, 172.3, 171.3, 158.2, 157.5, 138.6, 131.5, 130.5, 129.6, 129.2, 127.9, 116.4, 81.0, 58.3, 56.0, 52.4, 43.9, 43.5, 41.8, 38.9, 38.1, 28.9, 26.1, 23.6, 22.1$ ppm; MS (ESI): m/z 656.1 $[M+H]^+$, HRMS: m/z : calcd for $\text{C}_{33}\text{H}_{46}\text{N}_5\text{O}_9$: 656.3296; found: 656.3279.




HCl·H-Tyr(OH)-Gly-Gly-Phe-Leu-OH (Leu-enkephalin HCl)¹⁶

Boc-Tyr(OH)-Gly-Gly-Phe-Leu-OH (17.2 mg, 0.026 mmol) was submitted to gaseous HCl for 2 h. HCl·H-Tyr(OH)-Gly-Gly-Phe-Leu-OH (Leu-enkephalin HCl) was recovered as a white solid (15.4 mg, >99%).






^1H NMR (400 MHz, DMSO): $\delta = 9.40$ (s, 1H), 8.89–8.83 (m, 1H), 8.40–8.11 (m, 3H), 7.30–7.15 (m, 5H), 7.06 (d, $J = 8.5$ Hz, 2H), 6.71 (d, $J = 8.5$ Hz, 2H), 4.60–4.53 (m, 1H), 4.25–4.18 (m, 1H), 4.02–3.96 (m, 1H), 3.87–3.58 (m, 4H), 3.14–2.97 (m, 2H), 2.88–2.72 (m, 2H), 1.70–1.47 (m, 3H), 0.91 (d, $J = 6.4$, Hz, 6H), 0.85 (d, $J = 6.4$, Hz, 6H) ppm; ^{13}C NMR (400 MHz, DMSO): $\delta = 173.9, 171.2, 168.7, 168.3, 156.6, 137.8, 130.5, 129.3, 128.0, 126.3, 124.9, 115.3, 53.8, 50.3, 42.0, 41.6, 37.7, 36.1, 24.3, 22.9, 21.4$ ppm; MS (ESI): m/z 556.1 $[M+H]^+$.




Boc-Phe-Leu-OMe






Boc-Leu-Leu-OBn






Boc-Val-Phe-OMe






Boc-Leu-Pro-OBn






Boc-Ile-Ile-OMe






Boc-Gly-Phe-OMe






Boc-Gly-Pro-OBn






Boc-Tyr(Bn)-Leu-OMe






Boc-Phe-Phe-OMe






Boc-Phe-Leu-OBn






HCl·H-Leu-Leu-OBn






HCl·H-Val-Phe-OMe






HCl·H-Leu-Pro-OBn






HCl·H-Ile-Ile-OMe






HCl·H-Gly-Phe-OMe






HCl·H-Gly-Pro-OBn






HCl·H-Phe-Phe-OMe






HCl·H-Phe-Leu-OBn






Boc-Leu-Leu-Leu-OBn






Boc-Phe-Phe-Phe-OMe






Boc-Lys(Boc)-Gly-Pro-OBn






Boc-Trp-Val-Phe-OMe






Boc-Ile-Leu-Pro-OBn






Boc-Ile-Ile-Ile-OMe






Boc-Gly-Gly-Phe-OMe






Boc-Gly-Phe-Leu-OBn






HCl·H-Leu-Leu-Leu-OBn






HCl·H-Gly-Phe-Leu-OBn






Boc-Leu-Leu-Leu-Leu-OBn






Boc-Gly-Gly-Phe-Leu-OBn






HCl·H-Gly-Gly-Phe-Leu-OBn






Boc-Tyr(Bn)-Gly-Gly-Phe-Leu-OBn



Boc-Tyr(OH)-Gly-Gly-Phe-Leu-OH




HCl·H-Tyr(OH)-Gly-Gly-Phe-Leu-OH




Kinetic study

a) Conversion to Boc-Phe-Leu-OMe



<i>Time</i>	5	10	20	40
Ball-milling, ML = 22.5 mg/mL, EtOAc ($\eta = 1.4 \mu\text{L}/\text{mg}$)	46	91	95	95
Ball-milling, ML = 5.9 mg/mL, solvent-free ($\eta = 0 \mu\text{L}/\text{mg}$)	43	59	71	71
Ball-milling, ML = 22.5 mg/mL, solvent-free ($\eta = 0 \mu\text{L}/\text{mg}$)	12	17	56	65
Round-bottom flask with classical stirring, DMF ($\eta = 1.4 \mu\text{L}/\text{mg}$)	17	26	28	37
Round-bottom flask with classical stirring, EtOAc ($\eta = 1.4 \mu\text{L}/\text{mg}$)	4	8	9	12

b) Hydrolysis of Boc-Phe-NCA



<i>Time</i>	<i>5</i>	<i>10</i>	<i>20</i>	<i>40</i>
Ball-milling, ML = 22.5 mg/mL, EtOAc ($\eta = 1.4 \mu\text{L}/\text{mg}$)	0	1	2	2
Ball-milling, ML = 5.9 mg/mL, solvent-free ($\eta = 0 \mu\text{L}/\text{mg}$)	13	17	23	23
Ball-milling, ML = 22.5 mg/mL, solvent-free ($\eta = 0 \mu\text{L}/\text{mg}$)	1	5	12	19
Round-bottom flask with classical stirring, DMF ($\eta = 1.4 \mu\text{L}/\text{mg}$)	0	0	0	0
Round-bottom flask with classical stirring, EtOAc ($\eta = 1.4 \mu\text{L}/\text{mg}$)	0	0	0	0


General procedure for the coupling of Boc-amino acids with amino ester hydrochlorides under classical coupling conditions: To a solution of a Boc-(D or D,L)-Phe-OH (265 mg, 1 mmol, 1 eq.) in 5 mL of DMF were added successively HCl-H-Leu-OMe (181.6 mg, 1 mmol, 1 eq.), BOP (440 mg, 1.1 mmol, 1.1 eq.) and DIEA (0.435 mL, 2.5 mmol, 2.5 eq.). The resulting mixture was stirred for 3 h at room temperature and then concentrated under reduced pressure. The residue was diluted in EtOAc and the solution was neutralized with 10% aqueous solution of KHSO₄, washed with saturated aqueous solution of NaHCO₃ and brine, dried over MgSO₄, filtered and evaporated to yield the dipeptide.

Chiral HPLC analysis of Boc-(D,L)-Phe-Leu-OMe, Boc-D-Phe-Leu-OMe and Boc-L-Phe-Leu-OMe:

Boc-D-Phe-Leu-OMe prepared under classical conditions

Coupling of Boc-D-Phe-OH with HCl-H-Leu-OMe under the classical coupling conditions described above afforded the dipeptide Boc-D-Phe-Leu-OMe (383.1 mg, 98 %) as a white solid.


HPLC Chiralcel-OD (Hexane : *i*-PrOH) = (99 : 1), flow : 1mL/min



Boc-D,L-Phe-Leu-OMe prepared under classical conditions

Coupling of Boc-D,L-Phe-OH with HCl-H-Leu-OMe under the classical coupling conditions described above afforded the dipeptide Boc-D-Phe-Leu-OMe (335.2 mg, 85 %) as a white solid.


HPLC Chiralcel-OD (Hexane : *i*-PrOH) = (99 : 1), flow : 1mL/min



Boc-L-Phe-Leu-OMe prepared under ball-milling conditions from Boc-Phe-NCA

Coupling of Boc-Phe-NCA (37.1 mg, 0.127 mmol, 1 eq.) with HCl·H-Leu-OMe (21.1 mg, 0.127 mmol, 1 eq.) under ball-milling conditions described on page S2 afforded the dipeptide Boc-Phe-Leu-OMe (43.0 mg, 86 %) as a white solid.


HPLC Chiralcel-OD (Hexane : *i*-PrOH) = (99 : 1), flow : 1mL/min



Boc-L-Phe-Leu-OMe prepared under ball-milling conditions from Boc-Phe-OSu

Coupling of Boc-Phe-OSu (138.4 mg, 0.382 mmol, 1 eq.) with HCl·H-Leu-OMe (69.4 mg, 0.382 mmol, 1 eq.) under ball-milling conditions described on page S2 afforded the dipeptide Boc-Phe-Leu-OMe (123.8 mg, 83 %) as a white solid.

HPLC Chiralcel-OD (Hexane : *i*-PrOH) = (99 : 1), flow : 1mL/min



EcoScale calculation¹⁷

An EcoScale evaluation has been done for production of 10 mmoles of Boc-Tyr(Bn)-Leu-OMe starting from Boc-Tyr(Bn)-OSu, HCl·H-Leu-OMe and NaHCO₃ as the reagents and EtOAc as the grinding auxiliary, under ball-mill induced mixing.

	Details	Penalty point	
1. Yield	98%	1	
2. Price of reagents (to obtain 10 mmol of dipeptide)			
	NaHCO ₃ (0.858 g)	0	(1 kg = 5.5 USD)
	Boc-Tyr(Bn)-OSu (4.8 g)	5	(5 g = 96.4 USD)
	HCl·H-Leu-OMe (1.8 g)	0	(10 g = 29.0 USD)
	EtOAc (10.2 mL)	0	(5 L = 14.0 USD)
3. Safety			
	EtOAc	5	(F)
4. Technical Setup			
	Ball-mill	2	
5. Temperature/time			
	Room temperature, < 1h	0	
6. Workup and purification			
	Liquid-liquid extraction	3	

The sum of all penalty points is 16, which gives total score of **84** on the Ecoscale (an excellent synthesis).

Ecoscale evaluation for production of 10 mmoles of Boc-Tyr(Bn)-Leu-OMe starting from Boc-Tyr(Bn)-OSu, Et₃N and HCl·H-Leu-OMe as the reagents and DMF as the solvent, under classical agitation.⁷

1. Yield	96%	2	
2. Price of reaction reagents (to obtain 10 mmol of dipeptide)			
	Et ₃ N (1.4 mL)	0	(100 mL = 23.0 USD)
	Boc-Tyr(Bn)-OSu (4.8 g)	5	(5 g = 96.4 USD)
	HCl·H-Leu-OMe (1.9 g)	0	(10 g = 29.0 USD)
	DMF (17.1 mL)	0	(2.5 L = 6.3 USD)
3. Safety			
	Et ₃ N	10	(F, T)
	DMF	10	(F, T)
4. Technical Setup			
	Common setup	0	
5. Temperature/time			
	Room temperature, < 24h	1	
6. Workup and purification			
	Removal of solvent with bp > 150°C	2	
	Crystallization and filtration	1	

The sum of all penalty points is 31, which gives total score of **69** on the Ecoscale (an acceptable synthesis).

Ecoscale evaluation for production of 10 mmoles of Boc-Tyr(Bn)-Leu-OMe starting from Boc-Tyr(Bn)-OH, EtN(*i*Pr)₂, BOP reagent and HCl·H-Leu-OMe as the reagents and DMF as the solvent, under classical agitation.¹⁸

1. Yield	96%	2	
2. Price of reaction reagents (to obtain 10 mmol of dipeptide)			
	EtN(<i>i</i> Pr) ₂ (12.6 mL)	0	(100 mL = 37.1 USD)
	BOP reagent (4.6 g)	5	(5 g = 56.9 USD)
	Boc-Tyr(Bn)-OH (3.9g)	3	(5 g = 25.40 euros)
	HCl·H-Leu-OMe (1.9g)	0	(10 g = 37.60 euros)
	DMF (52 mL)	0	(2.5 L = 4.76 euros)
3. Safety			
	EtN(<i>i</i> Pr) ₂	10	(F, T)
	BOP reagent	10	(E)
	DMF	10	(F, T)
4. Technical Setup			
	Common setup	0	
5. Temperature/time			
	Room temperature, < 24h	1	
6. Workup and purification			
	Crystallization and filtration	1	

The sum of all penalty points is 42, which gives total score of **58** on the Ecoscale (an acceptable synthesis).

Milling-load calculations

The milling load (ML) can be defined as the sum of the mass of the reactants per free volume (V_f) in the jar. The free volume (V_f) is the volume of the jar minus the volume of the ball (V_{ball}). The milling load is expressed in mg/mL.

For the production of Boc-Phe-Leu-OMe from Boc-Phe-NCA, HCl·H-Leu-OMe and NaHCO₃, realised on a 0.10 mmol scale :

$$V_f = V_{ball\ mill} - V_{ball}$$

$$V_f = V_{ball\ mill} - (4/3)\pi r^3$$

$$V_f = 10 - (4/3)\pi 0.5^3$$

$$V_f = 10 - 0.524$$

$$V_f = 9.476\ \text{mL}$$

$$ML = (m_{\text{Boc-Phe-NCA}} + m_{\text{HCl}\cdot\text{H-Leu-OMe}} + m_{\text{NaHCO}_3})/V_f$$

$$ML = (29.1 + 18.2 + 8.4)/9.476$$

$$ML = 5.89\ \text{mg/mL}$$

For the production of Boc-Phe-Leu-OMe from Boc-Phe-NCA, HCl·H-Leu-OMe and NaHCO₃, realised on a 0.382 mmol scale :

$$ML = (m_{\text{Boc-Phe-NCA}} + m_{\text{HCl}\cdot\text{H-Leu-OMe}} + m_{\text{NaHCO}_3})/V_f$$

$$ML = (111.3 + 69.4 + 32.1)/9.476$$

$$ML = 22.5\ \text{mg/mL}$$

References

- ¹ A. Boruah, I. N. Rao, J. P. Nandy, S. K. Kumar, A. C. Kunwar and J. Iqbal, *J. Org. Chem.*, 2003, **68**, 5006.
- ² S. Hartwig, J. Schwarz and S. Hecht, *J. Org. Chem.*, 2010, **75**, 772.
- ³ W. Wu, Z. Zhang and L. S. Liebeskind, *J. Am. Chem. Soc.*, 2011, **133**, 14256.
- ⁴ K. M. Lassen, J. Lee and M. M. Joullié, *Tetrahedron Lett.*, 2010, **51**, 1635.
- ⁵ N. Umezawa, N. Matsumoto, S. Iwama, N. Kato and T. Higuchi, *Bioorg. Med. Chem.*, 2010, **18**, 6340.
- ⁶ S. Leleu, M. Penhoat, A. Bouet, G. Dupas, C. Papamicaël, F. Marsais and V. Levacher, *J. Am. Chem. Soc.*, 2005, **127**, 15668.
- ⁷ A. Berthelot, S. Piguel, G. Le Dour and J. Vidal, *J. Org. Chem.*, 2003, **68**, 9835.
- ⁸ P. Rzepecki, H. Gallmeier, N. Geib, K. Cernovska, B. König, and T. Schrader, *J. Org. Chem.*, 2004, **69**, 5168.
- ⁹ T. Kitamoto, S. Marubayashi and T. Yamazaki, *Tetrahedron*, 2008, **64**, 1888.
- ¹⁰ G. Papandrea and F. Ponticelli, *Synthetic Commun.*, 2008, **38**, 858.
- ¹¹ S. W. Larsen, M. Ankersen and C. Larsen, *Eur. J. Pharma. Sci.*, 2004, **22**, 399.
- ¹² J. H. Birkinshaw and Y. S. Mohammed, *Biochem. J.*, 1962, **85**, 523.
- ¹³ H. Nakagawa, K. Ohtsuka, K. Sugahara, C. Kobayashi, Y. Masuoka, K. Yamada and M. Kawase, *Tetrahedron: Asymmetry*, 2010, **21**, 659.
- ¹⁴ P. Tang, T. Furuya and T. Ritter, *J. Am. Chem. Soc.*, 2010, **132**, 12150.
- ¹⁵ C. Weina, W. Chao, Z. Ming and P. Shiqi, *Prep. Bioch. Biotech.*, 2003, **33**, 217.
- ¹⁶ A. Pinto, U. Hoffmanns, M. Ott, G. Fricker and N. Metzler-Nolte, *ChemBioChem*, 2009, **10**, 1852.
- ¹⁷ K. Van Aken, L. Strekowski and L. Patiny, *Beilstein J. Org. Chem.*, 2006, **2**, No. 3.
- ¹⁸ M. A. Sturgess and F. Kotch, *US Pat.*, US20100087466A1, 2010.